Cellectis Files Form 6-K with SEC

Ticker: CLLS · Form: 6-K · Filed: Nov 5, 2024 · CIK: 1627281

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, routine-disclosure

TL;DR

Cellectis filed a 6-K, confirming 20-F annual reports and Paris HQ. Standard stuff.

AI Summary

Cellectis S.A. filed a Form 6-K on November 5, 2024, to report information as a foreign private issuer. The filing indicates that Cellectis is submitting its report under the 1934 Securities Exchange Act and will file its annual reports under cover of Form 20-F. The company's principal executive office is located at 8, rue de la Croix Jarry, 75013 Paris, France.

Why It Matters

This filing is a routine disclosure for foreign private issuers, confirming their reporting obligations and providing basic company information to the SEC and investors.

Risk Assessment

Risk Level: low — This filing is a standard procedural report for a foreign private issuer and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing by Cellectis S.A.?

The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information to the SEC.

Which form does Cellectis S.A. use for its annual reports?

Cellectis S.A. indicates it files its annual reports under cover of Form 20-F.

Where is Cellectis S.A.'s principal executive office located?

Cellectis S.A.'s principal executive office is located at 8, rue de la Croix Jarry, 75013 Paris, France.

What is the Commission File Number for Cellectis S.A.'s SEC filings?

The Commission File Number for Cellectis S.A. is 001-36891.

Does Cellectis S.A. have any specific operational or financial updates in this filing?

This Form 6-K filing does not appear to contain specific operational or financial updates; it serves as a routine report of a foreign private issuer.

Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-11-05 16:35:05

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: November 5, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing